Table 3 Subgroup analysis of the effect of SGLT2i on blood pressure
Subgroup | MD | 95% CI | I2 (%) | P |
|---|---|---|---|---|
24H SBP | ||||
 SGLT2i | ||||
  Empagliflozin | − 7.30 | − 7.86, − 6.73 | 86.6 | 0.000 |
  Dapagliflozin | − 2.9 | − 6.09, 0.29 | – | 0.075 |
  Canagliflozin | − 4.4 | − 7.25, − 1.56 | 0.0 | 0.002 |
 Dose | ||||
  Large dose | − 7.41 | − 7.99, − 6.83 | 84.3 | 0.000 |
  Small dose | − 4.00 | − 5.70, − 2.30 | 22.3 | 0.000 |
 Course of treatment | ||||
  > 6 week | − 7.29 | − 7.85, − 6.72 | 87.1 | 0.000 |
  ≤ 6 week | − 3.94 | − 6.04, − 1.85 | 0.0 | 0.000 |
24H DBP | ||||
 SGLT2i | ||||
  Empagliflozin | − 4.90 | − 5.14, − 4.67 | 94.9 | 0.000 |
  Dapagliflozin | − 0.7 | − 2.87, − 1.47 | – | 0.52 |
  Canagliflozin | − 2.45 | − 4.12, − 0.78 | 0.0 | 0.004 |
 Dose | ||||
  Large dose | − 4.99 | − 5.23, − 4.75 | 0 | 0.000 |
  Small dose | − 2.11 | − 3.04, − 1.17 | 94.0 | 0.000 |
 Course of treatment | ||||
  > 6 week | − 4.90 | − 5.13, − 4.66 | 95.1 | 0.000 |
  ≤ 6 week | − 2.07 | − 3.36, − 0.77 | 0.0 | 0.002 |
Office systolic pressure | ||||
 SGLT2i | ||||
  Empagliflozin | − 6.03 | − 6.36, − 5.71 | 66.9 | 0.000 |
  Dapagliflozin | − 3.55 | − 4.98, − 2.13 | 0.0 | 0.000 |
 Dose | ||||
  Large dose | − 5.97 | − 6.29, − 5.65 | 72.4 | 0.000 |
  Small dose | − 4.1 | − 5.88, − 2.32 | 0.0 | 0.000 |
 Course of treatment | ||||
  ≤ 12 week | − 6.06 | − 6.39, − 5.72 | 68.3 | 0.000 |
  > 12 week | − 4.13 | − 5.29, − 2.98 | 0.0 | 0.000 |
Office diastolic pressure | ||||
 SGLT2i | ||||
  Empagliflozin | − 3.38 | − 3.58, − 3.18 | 97.0 | 0.000 |
  Dapagliflozin | − 0.99 | − 2.10, − 0.12 | 0.0 | 0.082 |
 Dose | ||||
  Large dose | − 3.40 | − 3.60, − 3.20 | 97.1 | 0.000 |
  Small dose | − 1.94 | − 2.71, − 1.17 | 0.0 | 0.000 |
 Course of treatment | ||||
  ≤ 12 week | − 4.09 | − 4.32, − 3.86 | 92.7 | 0.000 |
  > 12 week | − 1.44 | − 1.80, − 1.08 | 0.0 | 0.000 |